Creacion Ventures
VC Fund
Boston, United States
Creacion Ventures is a venture capital firm, focus on investment within the healthcare industry, particularly biopharma space.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Creacion Ventures invests in
Stages Creacion Ventures invests in
Countries Creacion Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Qingsheng Zhu
|
|||
Investment Focus
Industry
- Therapeutics 5 (45%)
- Biotechnology 5 (45%)
- Health Care 2 (18%)
- Pharmaceutical 2 (18%)
- Life Science 1 (9%)
Stage
- Series A 5 (45%)
- Series B 4 (36%)
- Series C 1 (9%)
Country
- United States 6 (55%)
- China 2 (18%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Qingsheng Zhu
Founding Partner
|
Founding Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xinmaide
|
Xinmaide focuses on the specialized fields of pulmonary drug delivery, nasal drug delivery, and brain drug delivery devices, dedicating its efforts to the research, design, and development of advanced medical technologies that improve how drugs are administered and absorbed in the body. | $43.7M / Series B / Apr 07, 2026 | |
Sirius Therapeutics
|
Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases. | $50M / Series B / May 09, 2025 | |
Odyssey Therapeutics
|
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $101M / Series C / Dec 05, 2023 | |
|
Sirius Therapeutics
|
Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases. | $60M / Series B / Oct 09, 2023 | |
QuantX Biosciences
|
QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products. | $45M / Series A / Jan 01, 2023 | |
Frontera Therapeutics
|
Frontera Therapeutics is an AAV gene therapy company with the mission to establish a low-cost and scalable platform, to develop and produce high-quality and affordably priced rAAV therapies for the global market. | $160M / Series B / Jun 24, 2022 | |
MOMA Therapeutics
|
MOMA Therapeutics operates as a biotechnology company. MOMA Therapeutics discover the next generation of precision medicines by targeting the molecular machines that underlie human disease. | $150M / Series B / May 10, 2022 | |
|
Odyssey Therapeutics
|
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $218M / Series A / Dec 07, 2021 | |
Parthenon Therapeutics
|
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks thesebarriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time. | $65M / Series A / Nov 03, 2021 | |
Pediatrix Therapeutics
|
Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options. | Series A / Apr 28, 2021 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Creacion Ventures invest in?
Creacion Ventures invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Creacion Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Creacion Ventures?
The team at Creacion Ventures includes Qingsheng Zhu (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
